A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

被引：59
作者：
Chu Q.S.C. [1 ]
Forouzesh B. [2 ]
Syed S. [2 ]
Mita M. [2 ]
Schwartz G. [3 ]
Copper J. [2 ]
Curtright J. [2 ]
Rowinsky E.K. [2 ]
机构：
[1] Cross Cancer Institute, Edmonton, Alta. T6G 1Z2
[2] Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX
[3] Brooke Army Medical Center, Fort Sam Houston, TX
来源：
Investigational New Drugs | 2007年 / 25卷 / 4期
关键词：
COL-3; Metalloproteinase inhibitor; Soft tissue sarcoma;
D O I：
10.1007/s10637-006-9031-6
中图分类号：
学科分类号：
摘要：
This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and MMP-9, on a continuous oral schedule at a dose of 50 mg/m2 daily in patients with advanced and/or metastatic soft tissue sarcoma (STS). The principal endpoints were the rate of objective tumor regression and the proportion of patients who did not experience disease progression during the first 8 weeks of treatment. Other study objectives included an assessment of pharmacology of COL-3, time to progression (TTP), and overall survival. A Simon two-stage design with multinomial stopping rule was employed, with 15 patients enrolled during the first stage of the study. Although COL-3 was generally well-tolerated, there were no objective responses and 5(33%) patients experienced disease progression during the first 8 weeks of treatment, which exceeded the criteria established a priori with regard to pursuing further evaluations of COL-3 in STS. The median values for TTP and survival were 109 and 279 days, respectively. Based on these results, further studies of COL-3 on this administration schedule in patients with STS are not warranted. © 2007 Springer Science+Business Media, LLC.
引用
收藏
页码：359 / 367
页数：8
相关论文
共 54 条
  • [1] Brennan M.F., Alektiar K.M., Maki R.G., Soft tissue sarcoma, Cancer: Principles and Practice of Oncology, 6th Edn, (2001)
  • [2] Bramwell V.H., Anderson D., Charette M.L., Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatoc soft tissue sarcoma, Cochrane Database Syst Rev, 3, (2003)
  • [3] Von Mehren M., New therapeutic strategies for soft tissue sarcomas, Curr Treat Options Oncol, 4, pp. 441-451, (2003)
  • [4] Hartmann J.T., Patel S., Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma, Drugs, 65, pp. 167-178, (2005)
  • [5] Liotta L.A., Stetler-Stevenson W.G., Metalloproteinases and cancer, Semin Cancer Biol, 1, pp. 99-106, (1990)
  • [6] Chambers A.F., Matrisian L., Changing view of the role of matrix metalloproteinases in metastases, J Natl Cancer Inst, 89, pp. 1260-1270, (1997)
  • [7] Hidalgo M., Eckhardt S.G., Development of Matrix Metalloproteinase inhibitors in cancer therapy, J Natl Cancer Inst, 93, pp. 178-193, (2001)
  • [8] Jeffrey J.J., Collagen and collagenase: Pregnancy and parturition, Semin Perinatol, 15, pp. 118-126, (1991)
  • [9] Talhouk R., Bisselm M., Werb Z., Coordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution, J Cell Biol, 118, pp. 1271-1282, (1992)
  • [10] Gonzales-Avila G., Iturria C., Vadillo F., Teran L., Selman M., Perez-Tamayo R., 72-kD (MMP-2) and 92 kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells, Pathobiology, 66, pp. 5-16, (1998)
123456